What is the main difference between MK-677 and CJC-1295?

MK-677 is an oral nonpeptide ghrelin-receptor agonist. The CJC-1295 studied in the cited human trials is a long-acting injected GHRH analog. They act through different receptors.

Which has better evidence for strength or function?

No head-to-head study establishes a winner. A 65-person MK-677 trial did not detect a significant strength or function improvement and was too small and short to rule one out. CJC-1295 studies measured GH and IGF-1 rather than these clinical outcomes.

Are either FDA approved?

Neither is FDA approved. Ibutamoren is also being studied as LUM-201 for pediatric growth hormone deficiency; development is not the same as approval.

Is the combination clinically validated?

No controlled human trial cited here establishes the safety or clinical benefit of combining them.

MK-677 vs CJC-1295: Mechanism and Human Evidence

Dossier labels summarize each dossier's research scope. They do not establish comparative treatment benefit or safety. Read the comparison below in that context.

Mechanisms and evidence

MK-677 (ibutamoren) is an oral, nonpeptide ghrelin-receptor agonist. CJC-1295 in the cited human trials is a long-acting, injected GHRH analog. FDA documents multiple CJC-1295-related substances and ambiguous naming in the human literature; results from one form should not be transferred to another. FDA ibutamoren evaluation; FDA CJC-1295 assessment; Teichman et al., PMID 16352683.

Question	MK-677	Studied CJC-1295
Human study context	Older adults and other distinct research populations	Short placebo-controlled studies in healthy adults
Demonstrated endpoint	Increased GH, IGF-1 and fat-free mass in the older-adult trial	Increased GH and IGF-1 after injection
Clinical benefit	No significant strength, function or visceral-fat benefit detected in the older-adult trial	Strength, function and fat-loss benefit not established by the cited hormone studies
FDA status	Not approved	Not approved

The randomized MK-677 study included 65 healthy adults aged 60–81. Fat-free mass increased, but strength and function did not improve significantly, and abdominal visceral fat did not decrease significantly. The authors explicitly said the study duration and participant number were insufficient to evaluate functional endpoints. Fasting glucose rose and insulin sensitivity fell; increased appetite, transient edema and muscle pain were reported. These observations do not define a comparative safety rate against CJC-1295. Nass et al., PMID 18981485.

Two short placebo-controlled CJC-1295 studies found sustained GH and IGF-1 increases in healthy adults. They were hormone and pharmacokinetic studies, not evidence of muscle, fat-loss or anti-aging benefit. A separate study assessed GH pulsatility after the long-acting analog. Teichman et al., PMID 16352683; Ionescu et al., PMID 17018654.

The FDA’s 2024 review states that Merck ended its earlier MK-0677 program in 1999 but that ibutamoren was subsequently developed as LUM-201. An official Phase 3 pediatric registration, NCT06948214, was marked recruiting in the September 29, 2026 registry archive. A registry status is dated development information, not proof of efficacy or approval. FDA review.

No cited head-to-head or combination trial supports a clinical ranking, synergy claim or regimen. This is an educational comparison, not medical advice.

MK-677 vs CJC-1295

MK-677

CJC-1295

Mechanisms and evidence

View Full Dossiers

Stay Updated on Peptide Comparisons